A mouse recapitulating APOL 1-associated kidney disease
C. Winkler
Abstract:nature medicine volume 23 | number 4 | APrIl 2017 411 pathways included cytokine–cytokine receptor genes, JAK–STAT and phagosome-related genes, a finding that implicates perturbations in immune pathways in mice expressing variant APOL1. Finally, the authors also found that both the variant and G0 forms of APOL1 are upregulated in glomeruli of patients with chronic kidney disease. Thus, chronic kidney disease itself, by upregulating APOL1, might potentiate the negative effects of the APOL1 variants. Studies have shown that APOL1 localizes to intracellular vesicles, and that altered endosome trafficking by variant APOL1 has a role in cytotoxicity2. The authors show here (Fig. 1) that expression of the APOL1 protein resulted in the accumulation of autophagosomes and late-endosomal vesicles, marked by RAB7, with impaired acidification, which was more pronounced for G1 and G2 variant proteins in both human embryonic kidney (HEK293) cells and immortalized human podocytes. Their data indicated that autophagosome maturation was disrupted in mice expressing APOL1 variants G1 and G2, as compared to wild-type mice, resulting in reduced autophagic flux. The researchers found that the reduced autophagic flux resulted in caspase-1-dependent inflammatory programmed cell death (pyroptosis), which was diminished by caspase-1 inhibitors in vitro. Furthermore, mice with a podocyte-specific deletion of Atg7 —required for autophagy—had increased inflammatory podocyte cell death as compared to wild-type mice, which points to a connection between decreased rates of autophagy and increased pyroptosis. In addition, there was an increase in protein levels and gene expression for markers of pyroptosis in kidneys from mice expressing the APOL1 G1 and G2 alleles. As the authors note, their findings open up new approaches for treating APOL1-associated kidney disease using approved pyroptosis inhibitors (i.e., interleukin (IL)-1), and potentially, caspase-1 inhibitors, which were previously shown to be safe in humans9. The APOL1-variant association with kidney disease poses several conundrums. First, only and those that do express variant APOL1 have not developed renal phenotypes4,7. Recently, an APOL1-transgenic mouse model with podocyte-specific, constitutive expression of variant-G2 APOL1 or reference-G0 APOL1 was found to exhibit pre-eclampsia, eclampsia, smaller litter sizes, and increased rates of maternal death and neonatal death of pups, but these mice did not develop kidney disease7. Because APOL1-mediated kidney disease in humans typically presents during adulthood, it is possible that levels of APOL1 transcription in surviving mice were too low to cause sufficient renal injury for kidney disease to develop over the life span of the mice. By generating mice with podocyte-specific, doxycycline-inducible expression of the APOL1 G0, G1 or G2 transgenes, Beckerman et al.6 avoided problems associated with in utero and neonatal exposure of mice to APOL1. The authors induced expression of the gene after weaning, and these mice developed kidney disease within a few weeks. Most of the mice expressing the G1 and G2 variants, but not those with the G0 variant, developed loss of the podocyte foot processes (effacement), scarring of the glomerulus (glomerulosclerosis), and severe albuminuria, a marker of glomerular injury. These effects were dose dependent. Notably, albuminuria in vivo diminished after expression of the APOL1 pathogenic variants was downregulated, recapitulating the resolution of HIV-associated nephropathy following HIV suppression in individuals with APOL1 high-risk genotypes. With regard to the human relevance of the mouse model, mice expressing the G1 and G2 variants had structural changes in their glomeruli that were similar to patterns of injury identified in renal biopsies from patients with APOL1associated kidney disease, including glomerulosclerosis and tubulointerstitial fibrosis8. Furthermore, mouse orthologs of several genes upregulated in patients with nephrotic syndrome carrying two APOL1 variant alleles were also upregulated in mice expressing the G1 and G2 variants of APOL1, when compared to reference-G0-carrying mice. Upregulated The discovery in 2010 that variants in the apolipoprotein L1 (APOL1) gene were strongly associated with a wide spectrum of nondiabetic kidney diseases in African Americans galvanized the kidney-disease research community, offering hope of improved diagnostics and a new target for drug development1. The coding variants, termed G1 and G2, are carried only by individuals with African ancestry and are striking because they are both common—13% of African Americans and 25% of West Africans carry two risk alleles (high-risk genotypes)—and have unusually high penetrance. Attempts to elucidate the mechanisms of APOL1-mediated renal injury have been hampered because the toxicity of the APOL1 protein confounds its modeling in mouse models and cell-culture studies2–4. The only known function of the APOL1 protein is to kill African trypanosomes through the permeabilization of the lysosomal and mitochondrial cell membranes4,5. The renal-disease risk variants probably rose to high frequency in West Africa because of their selective advantage against the trypanosomes that cause human African sleeping sickness. In this issue of Nature Medicine, Susztak and her colleagues have generated mice that have inducible, podocyte-specific expression of the APOL1 G1 or G2 variant alleles6. These mice share many of the hallmarks of APOL1associated kidney disease in humans, and the authors are able to elucidate a mechanism for the variant pathogenesis. These findings could open the door to new approaches to prevent and treat APOL1-associated kidney disease. Because of the toxicity of variant APOL1, and to a lesser degree, reference (G0) APOL1, it has been difficult to generate mouse models, A mouse recapitulating APOL1-associated kidney disease